个人中心 - 老虎社区

Dorash

IP属地：湖北

帖子 · 17帖子 · 17
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- DorashDorash
  ·2021-03-31
  不错
  非常抱歉，此主贴已删除
  1,961 评论
  点赞
  分享
  举报
- DorashDorash
  ·2021-03-24
  文章说q1今年收入1千万
  Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
  Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens
  Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
  2,084 评论
  点赞
  分享
  举报
- DorashDorash
  ·2021-03-24
  为啥这两只刚好是我买入的，目前浮亏一成了！
  These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts
  At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bot
  These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts
  2,461 评论
  点赞
  分享
  举报
- DorashDorash
  ·2020-11-25
  $盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？
  5,035 3
  点赞
  分享
  举报
- DorashDorash
  ·2020-09-21
  本来以为卖了美股就安全了，可是其他a股h也下跌啊
  非常抱歉，此主贴已删除
  2,690 评论
  2
  分享
  举报
- DorashDorash
  ·2020-06-08
  $枫叶教育(01317)$不错不错，值得关注！
  1,881 评论
  4
  分享
  举报
- DorashDorash
  ·2019-12-11
  $中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！
  3,943 1
  2
  分享
  举报
- DorashDorash
  ·2019-12-11
  $小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！
  3,679 1
  5
  分享
  举报
- DorashDorash
  ·2019-12-10
  $小米集团-W(01810)$K30在哪里买啊？官网还看不到！
  3,066 2
  2
  分享
  举报
- DorashDorash
  ·2019-12-10
  $小米集团-W(01810)$为啥股价还没有起色？
  1,774 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3464149602391943","uuid":"3464149602391943","gmtCreate":1501055582561,"gmtModify":1502690323634,"name":"Dorash","pinyin":"dorash","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":31,"tweetSize":17,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.14","exceedPercentage":"93.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.52%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"湖北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":354661149,"gmtCreate":1617167599781,"gmtModify":1617167599781,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"不错","listText":"不错","text":"不错","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354661149","repostId":"1168244531","repostType":2,"isVote":1,"tweetType":1,"viewCount":1961,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351885004,"gmtCreate":1616584915408,"gmtModify":1616584915408,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"文章说q1今年收入1千万","listText":"文章说q1今年收入1千万","text":"文章说q1今年收入1千万","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351885004","repostId":"2120700679","repostType":2,"repost":{"id":"2120700679","kind":"news","pubTimestamp":1615930509,"share":"https://www.laohu8.com/m/news/2120700679?lang=&edition=full","pubTime":"2021-03-17 05:35","market":"us","language":"en","title":"Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2120700679","media":"Zacks","summary":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens","content":"<html><body><p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.</p>\n<p>Over the last four quarters, the company has surpassed consensus EPS estimates two times.</p>\n<p>Kindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Kindred Bio shares have added about 13.7% since the beginning of the year versus the S&amp;P 500's gain of 5%.</p>\n<p><b>What's Next for Kindred Bio?</b></p>\n<p>While Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p>\n<p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p>\n<p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p>\n<p>Ahead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p>\n<p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.</p>\n<p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\n<a href=\"https://laohu8.com/S/KIN\">Kindred Biosciences, Inc.</a> (KIN) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/88Fg6KE6GPnh0zlh3tqRTA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2120700679","content_text":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.\nOver the last four quarters, the company has surpassed consensus EPS estimates two times.\nKindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nKindred Bio shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 5%.\nWhat's Next for Kindred Bio?\nWhile Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\nThere are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\nEmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\nAhead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\nIt will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.\nInvestors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nKindred Biosciences, Inc. (KIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":2084,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351083321,"gmtCreate":1616545959663,"gmtModify":1616545959663,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"为啥这两只刚好是我买入的，目前浮亏一成了！","listText":"为啥这两只刚好是我买入的，目前浮亏一成了！","text":"为啥这两只刚好是我买入的，目前浮亏一成了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351083321","repostId":"2107260553","repostType":2,"repost":{"id":"2107260553","kind":"news","pubTimestamp":1611851471,"share":"https://www.laohu8.com/m/news/2107260553?lang=&edition=full","pubTime":"2021-01-29 00:31","market":"us","language":"en","title":"These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2107260553","media":"TipRanks","summary":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bot","content":"<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Penny Stocks Could Rally All the Way to $11, Say Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-29 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/94euyTCm3Fsmi1L1JkZXKQ--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/G1wIt1b2ALiEE..QV7lnrw--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/24d79aa4d3847ec06a89abac7fdc7612","relate_stocks":{"BLRX":"BioLine Rx"},"source_url":"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2107260553","content_text":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meeting, and pointed out that unemployment, which has been rising in recent months. For market watchers seeking support, there is solace in the Fed’s monetary policy. The central bank is committed to buying $80 billion monthly in Treasury notes, and has put a rate increase on hold, likely until 2023.\nAt least one top strategist sees the current market environment in terms of opportunity. JPMorgan strategist Marko Kolanovic takes a bullish stance, writing, “We expect the global COVID pandemic to decline rapidly in the coming weeks. In fact, the pace of decline in new cases over the last 2 weeks is the highest on record both in the US and globally… Central Banks should remain accommodative given the elevated unemployment levels and over a decade of low inflation running below their targets… Short-term turmoil, such as the one this week, are opportunities to rotate from bonds to equities.”\nTaking this outlook into consideration, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. These stocks, priced at $5 or less, offer investors some of the highest growth potential available in the market. There is risk here, too, as the ‘pennies’ are often priced low for a reason, so due diligence is essential.\nUsing TipRanks’ database, we identified two penny stocks that have earned a “Strong Buy” consensus rating from the analyst community. Not to mention each offers up massive upside potential, as some analysts seem them climbing to $11.\nBioLineRx, Ltd. (BLRX)\nWe’ll start with BioLineRx, a clinical stage biopharma company focused on developing new cancer treatments. Oncology is a major field for cutting edge biopharmas. Cancer is frequently deadly, and frequently resistant to current treatments – and those treatments themselves will frequently cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates, but the most advanced is motixafortide, a synthetic peptide which has completed patient enrollment in a Phase 3 study on stem cell mobilization for autologous bone-marrow transplantation.\nThe drug is being studied for its efficacy in promoting the harvesting of bone marrow prior to the cancer treatment. Results from a pre-planned interim analysis showed ‘statistically significant evidence favoring treatment with motixafortide in the primary endpoint,’ evidence which was so significant that the enrollment was completed early, with 122 patients instead of 177. Stem cell mobilization, using motixafortide, is seen as the company’s most efficient path to registering the new drug for regulatory approval.\nBased on the potential of motixafortide and the $2.40 share price, some analysts think that now is the time to pull the trigger.\nCovering BLRX for Oppenheimer, 5-star analyst Mark Breidenbach noted, “Our thesis remains centered on motixafortide in stem cell mobilization, and we see a disconnect between the company’s market capitalization and motixafortide’s market opportunity as a stem cell mobilizer. Key GENESIS secondary endpoints are expected by mid-2021, and we see little risk heading into these data…”\nThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech.”\nGiven all of the above, Breidenbach rates BLRX as a Buy, and his $11 price target suggests a whopping 358% upside for the year ahead. (To watch Breidenbach’s track record, click here)\nThe rest of the Street appears to echo Breidenbach’s bullish sentiment. As it has racked up 3 Buys and no Holds or Sells, the consensus is unanimous: BLRX is a Strong Buy. Adding to the good news, the upside potential lands at ~428% based on the $12.67 average price target. (See BLRX stock analysis on TipRanks)\n\n\n\n\n\nKindred Biosciences (KIN)\nWhile most biotech companies focus on human medications, we are not the only market. Kindred biosciences is biopharmaceutical company in the veterinary market, developing biologic medications to improve the lives of our pets and working animals. The company describes its mission as ‘[bringing] to pets the same kinds of safe and effective medicines that human family members enjoy.’\nParvovirus (CPV) is a highly infectious, and highly lethal, viral disease affecting dogs. While vaccines are available, untreated cases can see upwards of 91% mortality. Kindred’s main pipeline drug, KIND-030 is under development as a treatment for this disease.\nCurrently, the drug candidate is following two paths in the development process – one for treatment of established infections, and one as a prophylactic preventative treatment for CPV. The prophylactic study has shown positive results, with treated dogs all avoiding infection, while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given as a treatment for infection. The drug candidate is in the pivotal study stage of development, the last before potential approval.\nLast month, Kindred announced that it had entered an agreement with Elanco Animal Health – a major manufacturer of veterinary medicines – for production of KIND-030.\nCantor analyst Brandon Folkes sees plenty of potential in Kindred, especially in the company’s agreement with Elanco.\n“A partnership with a leading animal health company, in this case Elanco, is exactly what the company needed, in our view. In our view, this validates KIN's new strategic approach, as a developer of drugs while seeking larger commercial partners. We believe that today's deal should reinforce to investors that there remains meaningful value in Kindred's pipeline, which could be realized over the next 12 to 18 months,” Folkes opined.\nKindred is also conducting studies of Tirnovetmab, or KIND-016, an antibody targeting IL31, in the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug started in the last quarter of 2020. There is a potentially huge market for a successful dermatitis treatment for canines; in the last six years, there has been a 47% increase in vet visits for dogs with severe itchy skin, and the market is estimated at $900 million or more.\n“While 2020 has been a tough year for KIN stock, the company continues to have multiple shots on goal from its diversified pipeline that could reward investors from the current levels. With multiple readouts in 2021, and the renewed sole focus on development of its pipeline we expect 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline, and in particular the atopic dermatitis portfolio,” the analyst summed up.\nTo this end, Folkes gives KIN an $11 price target, implying a 139% upside potential for 2021, and an Overweight (i.e. Buy) rating. (To watch Folkes’ track record, click here)\nKindred is another company with a unanimous Strong Buy analyst consensus, this one based on 5 recent Buy reviews. The stock has an average price target of $10.25, which suggests room for ~124% growth from the current trading price of $4.59. (See KIN stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":393155907,"gmtCreate":1606265652809,"gmtModify":1703842128908,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","listText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","text":"$盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/393155907","isVote":1,"tweetType":1,"viewCount":5035,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3502195913108179","authorId":"3502195913108179","name":"武贤普","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"idStr":"3502195913108179","authorIdStr":"3502195913108179"},"content":"转出来了吗","text":"转出来了吗","html":"转出来了吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":975665311,"gmtCreate":1600691907433,"gmtModify":1703822109336,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","listText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","text":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975665311","repostId":"1124902004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956339198,"gmtCreate":1591574003714,"gmtModify":1704195947188,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","listText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","text":"$枫叶教育(01317)$不错不错，值得关注！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956339198","isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910518949,"gmtCreate":1576044352981,"gmtModify":1704271128751,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","listText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","text":"$中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/910518949","isVote":1,"tweetType":1,"viewCount":3943,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537045207544484","authorId":"3537045207544484","name":"27个优质股","avatar":"https://static.tigerbbs.com/fde1daa28cae792e520759bac55bcdd3","crmLevel":2,"crmLevelSwitch":0,"idStr":"3537045207544484","authorIdStr":"3537045207544484"},"content":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","text":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","html":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910599969,"gmtCreate":1576035300951,"gmtModify":1704271093586,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","text":"$小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/910599969","isVote":1,"tweetType":1,"viewCount":3679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208675,"gmtCreate":1575964746197,"gmtModify":1704730216785,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","text":"$小米集团-W(01810)$K30在哪里买啊？官网还看不到！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/910208675","isVote":1,"tweetType":1,"viewCount":3066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208155,"gmtCreate":1575964724877,"gmtModify":1704730216094,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","text":"$小米集团-W(01810)$为啥股价还没有起色？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/910208155","isVote":1,"tweetType":1,"viewCount":1774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}